According to LiveMint, Hyderabad-based Aurobindo Pharma is planning to scale up its capacity as it expects more launches in its key U.S. market. It also plans to make India its sourcing hub for its generic drug business in Western Europe – a business that it had acquired from Actavis Plc.
The company’s capital outlay of $137 million for the next year will be used toward setting up three new plants including one that will produce semi-synthetic penicillin. The drug maker also added that it is developing fifteen products for itsoncology segment, and is planning a potential launch in 2018.
